Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Yixin Ningshen Tablets in the Preparation of Drugs for Treating Double Heart Disease

A technology of double heart disease and Yixinning, which is applied in drug combinations, nervous system diseases, cardiovascular system diseases, etc., can solve problems such as double heart disease that have not been seen in Yixin Ningshen Tablets, to protect heart function damage and improve mental state Effect

Active Publication Date: 2020-04-14
LIAONING HUANREN PHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there is no report on the use of Yixin Ningshen Tablets in the treatment of double heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Yixin Ningshen Tablets in the Preparation of Drugs for Treating Double Heart Disease
  • Application of Yixin Ningshen Tablets in the Preparation of Drugs for Treating Double Heart Disease
  • Application of Yixin Ningshen Tablets in the Preparation of Drugs for Treating Double Heart Disease

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0024] 1. Related materials

[0025] From June 27 to July 30, 2016, 98 male SD rats, weighing 220-260g, were selected from the Experimental Animal Center of Shenyang Pharmaceutical University, certificate number: SCXK (Liao) 2015-001. During the adaptation period (3d), the animals were kept in an environment with a light-dark cycle (light on 8:00) at a room temperature of 23±2°C, with free access to food and water. The rats were acclimatized for 3 days after being led, and administered continuously for 21 days. On the 22nd, the sleep deprivation model was started, and the modeling time was 10 days. Yixin Ningshen Tablets were continued to be given for treatment at the same time. On the 6th day of modeling and drug administration, the new object discrimination experiment was tested, on the 7th day, the elevated plus maze was tested, on the 8th day, the Y maze was tested, on the 9th day, the open field activity was tested, and on the 10th and 11th day, the electrocardiogram, orb...

experiment example 2

[0123] 1. Experimental time: July-August 2016.

[0124] 2. Experimental animals: SD rats, 75 males, weighing 160-180g, provided by the Experimental Animal Center of Shenyang Pharmaceutical University, certificate number: SCXK (Liao) 2015-001. During the adaptation period (3d), the animals were kept in an environment with a light-dark cycle (light on 8:00) at a room temperature of 23±2°C, with free access to food and water.

[0125] 3. Experimental grouping: 75 male SD rats, divided into 5 groups according to body weight, 15 in each group; model group, Yixin Ningshen Tablet 1 / 3×clinical equivalent (0.09g / kg), Yixin Ningshen Tablet 1× clinical equivalent dose (0.27g / kg), Yixin Ningshen Tablet 3× clinical equivalent dose (0.81g / kg), propranolol 1× clinical equivalent dose (15mg / kg) group . The specific experimental groups are shown in Table 12.

[0126] Table 12: Experimental grouping

[0127]

[0128] 4. Experimental method

[0129] 1) Electrocardiogram detection

[013...

experiment example 3

[0146] 1. Clinical data

[0147] From May 2015 to May 2016, 120 patients met the inclusion criteria in the outpatient and inpatient departments of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine. They were divided into the observation group and the control group according to the order of visit time by computer, with 60 people in each group.

[0148] 2. Diagnostic criteria:

[0149] 1) Diagnostic criteria for coronary heart disease:

[0150]Refer to the diagnostic criteria for coronary heart disease in the Guidelines for the Diagnosis and Treatment of Chronic Stable Angina Pectoris published by the Chinese Medical Association Cardiovascular Branch and the Editorial Committee of the Chinese Journal of Cardiovascular Diseases in 2007.

[0151] 2) Diagnostic criteria for anxiety and depression:

[0152] Refer to the "Chinese Mental Disorders Classification and Diagnostic Criteria Third Edition" issued by the Chinese Journal of Psychiatry in 2001 t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a mental stress relieving tablet in preparation of a medicine for treating a psychological heart disease. According to the invention, a large number of studies have shown that the mental stress relieving tablet can protect a cardiac function injury caused by insomnia and anxiety, can achieve the effect of improving psychological states through heart protection, has a dual-directional regulation effect, and can effectively treat the psychological heart disease.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicines, in particular to the application of Yixin Ningshen Tablets in the preparation of medicines for treating double heart diseases. Background technique [0002] Yixin Ningshen Tablets are produced by Liaoning SPH Good Nurses Pharmaceutical (Group) Co., Ltd., and the approval number is Z21021665. The active ingredients of this product are total saponins from stems and leaves of ginseng, Albizia vine, Schisandra chinensis and Ganoderma lucidum. Yixin Ningshen Tablets can invigorate qi and promote body fluid, nourish the heart and calm the nerves. It is used for insomnia, dreaminess, heart palpitations, and memory loss caused by heart qi deficiency and heart yin deficiency; neurasthenia sees the above syndromes. At the present stage, it should be mainly used in patients with insomnia, neurasthenia and anxiety. [0003] The total saponins of ginseng stems and leaves in Yixin Ningshen Tablet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/79A61K36/57A61K9/20A61P9/06A61P9/10A61P25/20A61P25/22
CPCA61K9/20A61K36/074A61K36/258A61K36/37A61K36/57A61K36/79A61K2236/331A61K2236/333A61K2236/39A61K2300/00
Inventor 李为理杨静玉席雪娇王芳郑继宇李国栋马振元吴琦秦培红
Owner LIAONING HUANREN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com